478
Participants
Start Date
January 26, 2018
Primary Completion Date
February 7, 2019
Study Completion Date
February 26, 2020
Bimekizumab
Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
Adalimumab
Adalimumab will be administered according to the labeling recommendations.
Placebo
Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
Ps0008 934, Washington D.C.
Ps0008 961, Rocky Mount
Ps0008 945, Greer
Ps0008 906, Boca Raton
Ps0008 936, Tampa
Ps0008 917, Troy
Ps0008 900, West Des Moines
Ps0008 905, Overland Park
Ps0008 932, Oklahoma City
Ps0008 931, Dallas
Ps0008 924, Houston
Ps0008 951, Houston
Ps0008 957, Glendale
Ps0008 927, Los Angeles
Ps0008 967, Santa Monica
Ps0008 955, San Diego
Ps0008 943, San Luis Obispo
Ps0008 929, Portland
Ps0008 939, Danbury
Ps0008 940, Beverly
Ps0008 925, Brighton
Ps0008 908, East Windsor
Ps0008 935, Winston-Salem
Ps0008 008, East Melbourne
Ps0008 004, Fremantle
Ps0008 007, Hectorville
Ps0008 010, Kogarah
Ps0008 005, Phillip
Ps0008 009, Woolloongabba
Ps0008 659, Calgary
Ps0008 663, Mississauga
Ps0008 660, Montreal
Ps0008 661, Peterborough
Ps0008 662, Toronto
Ps0008 664, Toronto
Ps0008 657, Waterloo
Ps0008 669, Windsor
Ps0008 670, Windsor
Ps0008 674, Winnipeg
Ps0008 207, Berlin
Ps0008 218, Bonn
Ps0008 203, Dresden
Ps0008 211, Hamburg
Ps0008 220, Hamburg
Ps0008 215, Lübeck
Ps0008 213, Mahlow
Ps0008 205, Osnabrück
Ps0008 217, Schweinfurt
Ps0008 252, Budapest
Ps0008 254, Budapest
Ps0008 255, Budapest
Ps0008 256, Debrecen
Ps0008 251, Gyula
Ps0008 260, Szeged
Ps0008 355, Bialystok
Ps0008 362, Bialystok
Ps0008 371, Bydgoszcz
Ps0008 352, Gdansk
Ps0008 359, Katowice
Ps0008 366, Katowice
Ps0008 363, Krakow
Ps0008 360, Lodz
Ps0008 372, Lodz
Ps0008 356, Lublin
Ps0008 364, Nowa Sól
Ps0008 353, Szczecin
Ps0008 354, Warsaw
Ps0008 365, Wroclaw
Ps0008 367, Wroclaw
Ps0008 373, Wroclaw
Ps0008 405, Saint Petersburg
Ps0008 401, Saratov
Ps0008 406, Yaroslavl
Ps0008 702, Gwangju
Ps0008 700, Seoul
Ps0008 754, Taipei
Ps0008 755, Taipei
UCB Biopharma SRL
INDUSTRY